(Q36816946)

16 August 2017

Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study (English)

1 reference

16 August 2017

Emily Y Chu

1

1 reference

16 August 2017

Karolyn A Wanat

2

1 reference

16 August 2017

Christopher J Miller

3

1 reference

16 August 2017

Ravi K Amaravadi

4

1 reference

16 August 2017

Leslie A Fecher

5

1 reference

16 August 2017

Marcia S Brose

6

1 reference

16 August 2017

Suzanne McGettigan

7

1 reference

16 August 2017

Lydia R Giles

8

1 reference

16 August 2017

Lynn M Schuchter

9

1 reference

16 August 2017

John T Seykora

10

1 reference

16 August 2017

Misha Rosenbach

11

1 reference

16 August 2017

language of work or name

English

0 references

publication date

18 May 2012

1 reference

Journal of the American Academy of Dermatology

16 August 2017

1 reference

16 August 2017

67

1 reference

16 August 2017

6

1 reference

16 August 2017

1265-1272

1 reference

Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

Dermatological phenotype in Costello syndrome: consequences of Ras dysregulation in development

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

The histologic spectrum of epithelial neoplasms induced by sorafenib

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

Dermatologic symptoms associated with the multikinase inhibitor sorafenib

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

Sorafenib-induced eruptive melanocytic lesions.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

Sunitinib: bridging present and future cancer treatment.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

HRAS and the Costello syndrome

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

Sorafenib in advanced clear-cell renal-cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

Keratoacanthomas associated with sorafenib therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

BRAF targeted therapy changes the treatment paradigm in melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

Sorafenib-induced multiple eruptive keratoacanthomas

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

The Raf-MEK-ERK cascade represents a common pathway for alteration of intracellular calcium by Ras and protein kinase C in cardiac myocytes.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern?

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

[Squamous cell carcinoma in a patient receiving sorafenib].

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

RAF inhibition and induction of cutaneous squamous cell carcinoma.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4838029

Subungual keratoacanthoma

5 September 2018

1 reference

12 December 2020

Ultraviolet A and photosensitivity during vemurafenib therapy

1 reference

12 December 2020

Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1

1 reference

12 December 2020

1 reference

12 December 2020

Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib

1 reference

12 December 2020

Verrucous papules and plaques in a pediatric patient: cutaneous papillomas associated with Costello syndrome

1 reference

12 December 2020

Invasive squamous cell carcinoma and sorafenib in a black patient

1 reference

12 December 2020

MC1R germline variants confer risk for BRAF-mutant melanoma

1 reference

12 December 2020

10.1016/J.JAAD.2012.04.008

Identifiers

DOI

1 reference

16 August 2017

1 reference

16 August 2017

PubMed publication ID

22609219

1 reference